文献速递消化、代谢与肾脏急症

线粒体ATP敏感性钾通道高亲和力与低亲和力磺脲类药物在二甲双胍治疗的2型糖尿病患者中的心血管结局比较

Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin.
PubMed 文献 · JAMA Netw Open · 2022-12-01
一句话结论在二甲双胍治疗的2型糖尿病患者中,高亲和力磺脲类药物(格列本脲、格列吡嗪)较低亲和力药物(格列齐特、格列美脲)与主要不良心血管事件风险增加相关(aHR 1.18)。

该研究为台湾糖尿病健康数据库2006至2017年的新使用者、活性对照、倾向评分匹配队列研究,比较二甲双胍基础上联用线粒体ATP敏感性钾通道高亲和力磺脲类药物(格列本脲、格列吡嗪)与低亲和力药物(格列齐特、格列美脲)的2型糖尿病患者。每组各53 714例。高亲和力组较低亲和力组主要不良心血管事件风险增加(aHR 1.18;95% CI 1.03-1.34),心肌梗死(aHR 1.34;95% CI 1.04-1.73)、全因死亡(aHR 1.27;95% CI 1.03-1.57)和严重低血糖(aHR 1.82;95% CI 1.58-2.10)风险亦增加,但缺血性卒中、心血管死亡、心律失常和心力衰竭风险未增加。用药后1至90天主要不良心血管事件风险最高(aHR 6.06;95% CI 4.86-7.55)。作者认为高亲和力阻断线粒体ATP敏感性钾通道可能解释磺脲类药物相关的主要不良心血管事件。

要点

  • 在二甲双胍治疗的2型糖尿病患者中,高亲和力磺脲类药物(格列本脲、格列吡嗪)较低亲和力药物(格列齐特、格列美脲)主要不良心血管事件风险增加(aHR 1.18;95% CI 1.03-1.34)。
  • 高亲和力组心肌梗死风险增加(aHR 1.34;95% CI 1.04-1.73),全因死亡风险增加(aHR 1.27;95% CI 1.03-1.57)。
  • 高亲和力组严重低血糖风险增加(aHR 1.82;95% CI 1.58-2.10)。
  • 高亲和力组缺血性卒中、心血管死亡、心律失常和心力衰竭风险未增加。
  • 开始高亲和力磺脲类药物后1至90天主要不良心血管事件风险最高(aHR 6.06;95% CI 4.86-7.55)。

适用人群与场景

  • 接受二甲双胍治疗的2型糖尿病患者,来自台湾糖尿病健康数据库2006至2017年数据。
  • 新使用者、活性对照、倾向评分匹配的队列人群;每组53 714例,平均(标准差)年龄54.7(12.1)岁,男性31 962例(59.5%)。

研究设计与关键结果

  • 研究设计:新使用者、活性对照、倾向评分匹配队列研究,分析台湾糖尿病健康数据库2006至2017年数据;数据分析于2020年8月至2021年7月进行。
  • 暴露:心脏线粒体ATP敏感性钾通道高亲和力磺脲类药物(格列本脲和格列吡嗪)与低亲和力磺脲类药物(格列齐特和格列美脲)分别联合二甲双胍。
  • 主要终点:主要不良心血管事件(心血管死亡或心肌梗死或缺血性卒中住院的复合终点)。
  • 高亲和力组较低亲和力组主要不良心血管事件风险增加(aHR 1.18;95% CI 1.03-1.34)。
  • 高亲和力组较低亲和力组心肌梗死风险增加(aHR 1.34;95% CI 1.04-1.73)。
  • 高亲和力组较低亲和力组全因死亡风险增加(aHR 1.27;95% CI 1.03-1.57)。
  • 高亲和力组较低亲和力组严重低血糖风险增加(aHR 1.82;95% CI 1.58-2.10)。
  • 高亲和力组较低亲和力组缺血性卒中、心血管死亡、心律失常和心力衰竭风险未增加。

证据类型、等级与局限

  • 证据类型:新使用者、活性对照、倾向评分匹配队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,高亲和力阻断线粒体ATP敏感性钾通道可能解释磺脲类药物相关的主要不良心血管事件。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Sulfonylureas are frequently used as add-on to metformin in type 2 diabetes (T2D), and individual sulfonylurea agents carry different risks of cardiovascular disease. Sulfonylureas' different affinities to cardiac mitochondrial adenosine triphosphate-sensitive potassium (mitoKATP) channels have been speculated to account for the intraclass difference in cardiovascular risk from in vitro and ex vivo studies; however, this hypothesis has not been assessed in a general population with diabetes receiving sulfonylureas added to metformin.

OBJECTIVE: To compare the risk of myocardial infarction (MI), ischemic stroke, or cardiovascular death in patients with T2D treated with mitoKATP channel high-affinity sulfonylureas and low-affinity sulfonylureas as add-on to metformin.

DESIGN, SETTING, AND PARTICIPANTS: This is a new-user, active-comparator, and propensity score-matched cohort study with analysis of the Taiwanese Diabetes Mellitus Health Database from 2006, to 2017. Data analysis was performed from August 2020 to July 2021.

EXPOSURES: Cardiac mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride) sulfonylureas combined with metformin.

MAIN OUTCOMES AND MEASURES: Primary outcome was major adverse cardiovascular events (MACEs), a composite of cardiovascular death or hospitalization for either MI or ischemic stroke. Secondary outcomes included individual MACE components, heart failure, arrhythmia, all-cause mortality, and severe hypoglycemia. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs).

RESULTS: Each sulfonylurea group comprised 53 714 patients (mean [SD] age, 54.7 [12.1] years; 31 962 men [59.5%]). MitoKATP channel high-affinity sulfonylureas vs low-affinity sulfonylureas when combined with metformin were associated with an increased risk of MACE (aHR, 1.18; 95% CI, 1.03-1.34), MI (aHR, 1.34; 95% CI, 1.04-1.73), all-cause mortality (aHR, 1.27; 95% CI, 1.03-1.57), and severe hypoglycemia (aHR, 1.82; 95% CI, 1.58-2.10), but not with increased risks of ischemic stroke, cardiovascular death, arrhythmia, and heart failure. The duration analyses revealed the highest MACE risk during 1 to 90 days after initiation of mitoKATP channel high-affinity sulfonylureas (aHR, 6.06; 95% CI, 4.86-7.55).

CONCLUSIONS AND RELEVANCE: Use of mitoKATP channel high-affinity sulfonylureas vs low-affinity sulfonylureas was associated with an increased MACE risk in patients with T2D concomitantly receiving metformin, suggesting that high-affinity blockage of the mitoKATP channels could account for sulfonylurea-associated MACEs.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Wang MT, Pan HY, Huang YL, et al. Comparison of Mitochondrial Adenosine Triphosphate-Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin. JAMA Netw Open. 2022. PMID: 36484988. doi:10.1001/jamanetworkopen.2022.45854

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。